Discrete populations of stem cells reside within placental tissue (amnion, chorion, and umbilical cord matrix). Because of the ease of collection, and the abundance of placental tissue harvested after birth, there is a growing interest in using these stem cells for tissue regenerative medicine purposes. Placental stem cells, have multi-lineage potential beyond that of adult, bone marrow-derived mesenchymal stem cells (MSC), with the ability to differentiate to all three germ layers (ectoderm, endoderm, and mesoderm) in vivo. Amnion, chorion, and umbilical cord matrix stem cells (UCM-SCs) all demonstrate immunosuppressive effects similar to bone marrow derived MSC, indicating that allogeneic transplantation of these cells for regenerative therapies may be possible. In fact, allogeneic bone marrow-derived MSC are currently being evaluated as a therapeutic for steroid refractory graft versus host disease in Phase III studies, providing a precedent for the use of allogeneic stem cells in a clinical setting. The tissue regenerative capacity of placental stem cells, however, remains unclear. Furthermore, the utility of banked allogeneic placental stem cells for skeletal tissue repair has not yet been tested. In this proposal, we will examine the skeletal regenerative potential of autologous and allogeneic placental stem cells. In collaboration with the UC Davis Center for Equine Health and UC Davis, we will use horses as a non-terminal, large animal model to explore the feasibility of banking autologous and allogeneic equine placental stem cells for musculoskeletal regenerative medicine applications. The equine studies described in this narrative provide a unique opportunity to bring novel cell based therapies to the veterinary market, while also modeling allogeneic placental stem cells as a treatment for orthopedic injuries in humans.

Public Health Relevance

Adult mesenchymal stem cells hold great promise for treating a multitude of diseases and injuries, including limb ischemia associated with diabetes, chronic skin ulcers, and bone fractures. In this proposal, we will examine the therapeutic potential of allogeneic umbilical cord matrix stem cells isolated from placental tissue. We believe that these primitive stem cells, harvested from tissue at birth and banked for later therapeutic applications, hold even greater tissue repair and regeneration potential than adult derived cells. Our studies will define the therapeutic potential of these cells and help bring novel stem cell therapies to the clinic.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AG033965-01
Application #
7671730
Study Section
Special Emphasis Panel (ZRG1-MOSS-H (04))
Program Officer
Kohanski, Ronald A
Project Start
2009-06-01
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$270,293
Indirect Cost
Name
Thermogenesis Corporation
Department
Type
DUNS #
175719335
City
Rancho Cordova
State
CA
Country
United States
Zip Code
95742